Skip to main content
editorial
. 2018 Nov 29;2(6):e162. doi: 10.1097/HS9.0000000000000162

Figure 1.

Figure 1

Immune dysregulation in MDS. MDS is characterized by dysregulation of the adaptive as well as the innate immune system. Autoimmune mechanisms (AI-MDS, left panel) and myeloid-derived inflammation (MDI-MDS, right panel) contribute to specific phenotypes in low- and high-risk MDS, which can be targeted by immune modulatory therapies. DC = dendritic cell, HSPC = hematopoietic stem and progenitor cell, MDI = myelodysplastic syndrome, MDSC = myeloid-derived suppressor cell, MSC = mesenchymal stromal cell.